Allergy Delabeling in Antibiotic Stewardship - Evaluations
Launched by UNIVERSITY OF PENNSYLVANIA · May 2, 2025
Trial Information
Current as of July 27, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The RENEW-EVAL clinical trial is focused on understanding the challenges of introducing a new approach to managing patients with a specific allergy to beta-lactam antibiotics, which are commonly used to treat infections. This study is particularly looking at patients who have blood cancers, such as lymphoma, leukemia, or myeloma, and who currently have a record indicating they are allergic to these antibiotics. The researchers want to find out how to better integrate this new approach into everyday medical care for these patients.
To be eligible for the trial, patients must be hospitalized for their cancer treatment and have a documented allergy to beta-lactam antibiotics. The study is not currently open for recruitment, but it aims to include adult patients aged 65 to 74, along with their healthcare providers. Participants will share their experiences and insights during the study, which will help improve future care for patients with blood cancers. It’s important to note that not everyone will qualify for the study, as certain medical conditions could exclude potential participants.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Patient participants:
- • a diagnosis of a hematologic malignancy (lymphoma, leukemia, myeloma)
- • a prior label applied to their medical record to indicate a beta lactam allergy
- • hospitalized as an inpatient to an oncology service at the time the study is conducted
- Clinician participants:
- • member of the primary inpatient care team
- Exclusion Criteria:
- Patient participants:
- • meet one of the exclusionary criteria for the RENEW clinical intervention
- Clinician participants:
- • no exclusions
About University Of Pennsylvania
The University of Pennsylvania, a prestigious Ivy League institution located in Philadelphia, is renowned for its commitment to advancing medical research and improving healthcare outcomes. As a clinical trial sponsor, the university leverages its extensive resources, interdisciplinary expertise, and cutting-edge facilities to conduct innovative studies across various therapeutic areas. With a focus on translating scientific discoveries into clinical applications, the University of Pennsylvania fosters collaborations among leading researchers, clinicians, and industry partners, ensuring rigorous trial design and adherence to ethical standards. Through its dedication to excellence in research and education, the university plays a pivotal role in shaping the future of medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported